Inhaled treprostinil improves forced vital capacity in patients with pulmonary hypertension associated with ILD

Inhaled treprostinil was associated with improvements in forced vital capacity (FVC) in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) compared with placebo at 16 weeks, according to a study.

According to the results of this post-hoc analysis, which included 327 patients enrolled in the INCREASE trial, improvement in FVC was most seen in patients with idiopathic pulmonary fibrosis (IPF), demonstrating the potential benefit of inhaled treprostinil therapy in these patients.

“I am encouraged by the improvement in FVC observed in subgroups such as IPF in this post-hoc analysis of the INCREASE study data,” said Steven Nathan, MD, an INCREASE study investigator and Steering Committee member, Director of the Advanced Lung Disease Program and Director of the Lung Transplant Program at Inova Fairfax Hospital in Falls Church, VA, and Professor of Medicine at Virginia Commonwealth University-Inova Campus, in a press release. “These data, collected in patients presenting with IPF plus pulmonary hypertension, warrant the further investigation of inhaled treprostinil’s effects in patients diagnosed with IPF alone, before their disease progresses and they develop pulmonary hypertension.”

Reference
Nathan SD, Waxman A, Rajagopal S, et al.Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Lancet Res Med. 2021; DOI:https://doi.org/10.1016/S2213-2600(21)00165-X.